Chu Yu-Waye Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
7
Insider Sells Sum
$1.05M

Insider Activity of Chu Yu-Waye

According to the SEC Form 4 filings, Chu Yu-Waye, being in a position of

  1. Chief Medical Officer at CytomX Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 21279 shares for $136,675,
    over all time since 2025-03-18, has bought 0 shares, and sold 25304 shares for $139,086.

Biography of Chu Yu-Waye

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $136,6751100

Comparison of Insiders on Amount of Buys and Sells

2026-03-17SaleCytomX Therapeutics, Inc.
CTMX
Chief Medical Officer
21,279
0.0148%
$6.42$136,675-37.25%
2025-03-18SaleCytomX Therapeutics, Inc.
CTMX
Chief Medical Officer
4,025
0.005%
$0.60$2,411+338.96%
2023-04-18SaleFate Therapeutics, Inc.
FATE
Chief Medical Officer
2,532
0.0027%
$6.57$16,648-26.89%
2023-01-10SaleFate Therapeutics, Inc.
FATE
Chief Medical Officer
7,825
0.0076%
$5.24$41,003-13.84%
2022-04-19SaleFate Therapeutics, Inc.
FATE
Chief Medical Officer
4,062
0.004%
$35.37$143,673-43.08%
2022-01-11SaleFate Therapeutics, Inc.
FATE
Senior VP Clinical Development
3,965
0.0042%
$48.51$192,340-43.63%
2021-12-10SaleFate Therapeutics, Inc.
FATE
Senior VP Clinical Development
7,500
0.0083%
$51.46$385,948-38.95%
2021-04-16SaleFate Therapeutics, Inc.
FATE
Senior VP Clinical Development
3,275
0.0036%
$83.30$272,809-25.9%
Total: 8
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.